2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2555

Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjogren’s Syndrome
Abstract Number: 2157

Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
Abstract Number: 388

Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry
Abstract Number: 636

Retrospective Study of Allogenic Mesenchymal Stem Cells Transplantation in Active and Refractory Lupus Nephritis for Induction Therapy
Abstract Number: 200

Rheumatic Manifestations and Connective Tissue Diseases in Autoimmune Hepatitis of the Child and the Adult
Abstract Number: 1272

Rheumatoid Arthritis (RA) Incomplete Secondary Responders to TNF-Alpha Safely Achieve Efficacy by Switching to Certolizumab Pegol in a 24-Week Study: A Phase IV, Randomized Multicenter, Double-Blind, Twelve-Week Study Followed by a 12 -Week Open-Label Phase
Abstract Number: 2127

Rheumatoid Arthritis (RA) Patients Discordant for Rheumatoid Factor and Anti-CCP Positivity Have Different Clinical and Laboratory Features Than RA Patients Seropositive or Seronegative for Both Markers
Abstract Number: 2630

Rheumatoid Arthritis and Osteoarthritis in the Population: How Different Is the Impact?
Abstract Number: 1229

Rheumatoid Arthritis and Risks of Malignant Lymphoma – Are Risks Still Increased?
Abstract Number: 1287

Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals
Abstract Number: 1224

Rheumatoid Arthritis Disease Activity During Pregnancy Affects the Postnatal Catch-up Growth of the Child
Abstract Number: 2479

Rheumatoid Arthritis Does Not Increase Risk of Short Term Total Knee Replacement (TKR) Adverse Events (AE)
Abstract Number: 1231

Rheumatoid Arthritis Is Associated with Likelihood of Being Overweight in Women
Abstract Number: 1765

Rheumatoid Arthritis Is Associated with Signaling Alterations in Naturally Occurring Autoreactive B-Lymphocytes
Abstract Number: 1262

Rheumatoid Arthritis Patients with Higher Disease Severity and Subclinical Carotid Plaque Experience More Cardiovascular Events Despite a Favorable Conventional Cadiovascular Risk Profiles

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].